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ABSTRACT 
This paper provides a summary of the areas of survival from childhood, teenage and young adult 
cancer and the significant late-effects that can arise from treatment with particular focus on the 
area of reproductive health and the impact on both fertility and pregnancy. To complete this 
UHYLHZ:HERI6FLHQFHDQG0('/,1(ZHUHXVHG6HDUFKWHUPVLQFOXGHG³VXUYLYDO$1'
FKLOGKRRG25WHHQDJH25\RXQJDGXOWFDQFHU´³ODWHHIIHFWV´³FKLOGKRRGFDQFHU´³WHHQDJH
DQGRU\RXQJDGXOWFDQFHU´³DQGIHUWLOLW\DIWHUFDQFHU´³SUHJQDQF\DIWHUFDQFHU´DQG³IHUWLOLW\
SUHVHUYDWLRQ´$GGLWLRQDOO\FOLQLFDOH[SHUWLVHIURPWKHDXWKRUVZDVGUDZQXSRQ Childhood 
cancer is thankfully a rare occurrence; however, the incidence is increasing. Survival rates 
remain high and this means that a growing population of childhood and young adult cancer 
survivors is reaching adulthood. For some of these adults, whilst cured of their cancer they are 
now facing a future with lasting effects on their health from their treatments. These effects, 
commonly referred to as Late Effects are defined as health problems related either directly to the 
underlying cancer or to its treatment and which occur months or years after treatment has 
finished. Reproductive health is an important consideration for these patients, and whilst many 
will be able to conceive naturally, some will exhibit impaired fertility after their treatments. This 
can include difficulties at all points along the path from conception to delivery of a live, healthy 
offspring. High quality, large population evidence is sparse in many areas relating to fertility risk 
from treatment and into the maternal and fetal health of childhood cancer survivors. Yet given 
the potential for complications the authors advocate consideration of fertility at the time of 
diagnosis and prior to potentially gonadotoxic treatment. 
 
Keywords 
childhood cancer, childhood cancer, teenage cancer, young adult cancer, survival, reproductive 
health, fertility, fertility preservation 
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Abbreviations  
TYA ± teenage and young adult 
CYP ± cKLOGUHQDQG\RXQJSHRSOH¶V 
LEs ± late effects 
 
Key Message 
Whilst childhood cancer is rare, survival from childhood cancer is thankfully high. 
Consideration of the impact of the disease itself and iatrogenic late effects of treatment are 
important factors in the long-term health of cancer survivors. 
 
1. CHILDHOOD CANCER  
Cancer in childhood is a rare entity, with those diagnosed before their fifteenth birthday 
accounting for 1% of total cancer diagnoses in the developed world1 2. However, over the past 
four decades there has been an increase of approximately 25% in the number of childhood 
cancer cases diagnosed across Europe and North America and2 3 4. Similarly, teenage and young 
adult (TYA) cancer (diagnosed between the ages of 15 and 24 years) has  risen significantly in 
this time period2 5 6. TYA and childhood cancer are together known as children and young 
SHRSOH¶V&<3FDQFHU5DWHVRI&<3FDQFHUYDry widely. Age standardised rates of cancer in 
those under 20 years old across Europe range from 122.4 in some areas of Poland to 234.2 in 
parts of Italy, with similar ranges being seen across Oceania and North America2. 
Cancers in CYPs present an important health issue as a result of potential attendant mortality and 
morbidity. Cancer is the leading cause of death in children, accounting for around 20% of deaths 
in 1 to 14 year olds7. It is the leading cause of death in female TYAs, and the leading cause of 
death from disease in male TYAs, although transport accidents account for more deaths in this 
group8. The potential years of life lost to cancer and economic sequelae are much greater when it 
affects CYPs compared to older individuals9. Mortality rates vary significantly throughout 
Europe, from around eighteen deaths per million children in Norway to almost sixty deaths per 
million in the Ukraine10. Similar variability is seen in TYA cancers, where survival is 
significantly better in the Nordic countries compared to the United Kingdom, Spain and Italy11. 
As well as being a leading cause of mortality, CYP cancer results in significant morbidity and 
associated cost12, wiWKPXFKRIWKLVPRUELGLW\SHUVLVWLQJIRUWKHGXUDWLRQRIWKH&<3¶VOLIH13.  
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1.1 Childhood Cancer Survival 
Since the late 1970s, in the same time period that CYP cancer incidence has increased, survival 
rates for childhood cancer have more than doubled2 14.  Over 80% of CYP diagnosed with cancer 
in the developed world are now expected to survive their illness15.  Adult survivors of CYP 
cancer, therefore, account for an ever increasing proportion of the general population. 
Despite medical and scientific advances resulting in CYP cancer being an increasingly 
survivable condition13 14, survival often comes with associated morbidity and costs. Traditional 
cancer treatments, such as chemotherapy and radiotherapy, are generally both non-specific and 
frequently associated with adverse effects, meaning that many CYP cancer survivors will be at 
risk of developing subsequent health issues, some of which are not apparent until many years 
after treatment has ended16. Adults who have survived childhood cancer are 3 times more likely 
to die 35 years after diagnosis than age- and sex-matched controls who have not had a cancer 
diagnosis17. By 25 years post diagnosis, over two thirds of survivors will have at least one 
chronic health condition18 and four in five will have at least one serious long-term illness by the 
age of 4519 with some estimates being even higher20.  
 
1.2. Late Effects of Cancer and Treatment 
7KHWHUP³ODWHHIIHFWV´/(VIURP&<3¶VFDQFHUUHIHUVWRKHDOWKSUREOHPVUHODWHGHLWher directly 
to the underlying cancer or to its treatment and which occur months or years after treatment has 
finished. LEs affecting almost all systems have been described, with prevalence varying 
depending on cancer diagnosis and treatment modality as well as demographic and lifestyle 
factors. 
Given the vastly improved survival now seen in CYP cancer, it is imperative that treatment aims 
not only to cure the underlying disease but to do so with minimal impact on future health: Large, 
multinational, studies have been set up aiming to fully explore the LEs of CYP cancer and to 
research how best to improve the lives of survivors21 22. Many contemporary trials are 
investigating the safety of reduced treatment intensities, which should help to reduce the 
incidence of LEs23 24. 
This review aims to provide a brief overview of the vast array of LEs experienced by survivors 
of CYP cancer in order to contextualise the issues they might experience whilst providing a 
more in-depth review of the reproductive health sequelae. 
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1.2.i Second Primary Neoplasms 
Second primary neoplasms (SPNs) are further cancer diagnoses which are distinct from 
recurrence  of the original tumour25. The possibility of SPNs causes significant anxiety to 
survivors and their families26. By 25 years post treatment, around 4% of survivors will have 
developed a further malignancy27. 
 
1.2.ii Cardiovascular Disease 
Cardiovascular disease, including congestive cardiac failure, , myocardial infarction and 
vascular disease may affect survivors of CYP cancer, with prevalence of roughly 4-6 times that 
seen in the non-cancer population with the cumulative incidence continuing to increase 30 years 
after cancer diagnosis28 29. This increased risk is particularly notable amongst survivors of 
certain tumour types (eg lymphoma) and those receiving particular treatments (eg high dose 
anthracyclines or mediastinal/chest radiation)21 22. Stroke risk is additionally increased in CYP 
cancer survivors, with 12% reporting at least one stroke by 30 years post diagnosis30, and a fifth 
of these experiencing recurrent strokes31. 
 
1.2.iii Endocrine Disorders 
Endocrine disorders are particularly prevalent amongst survivors of CYP cancer, with one large 
study reporting that 44% of survivors had at least one endocrine disorder, with survivors of 
+RGJNLQ¶VO\PSKRPDDQGFHQWUDOQHUYRXVV\VWHPWXPRXUVEHLQJDWJUHDWHVWULVN32. At least some 
of this endocrine pathology may relate to high rates of obesity and metabolic syndrome, which is 
associated with diabetes mellitus and seen in almost one third of cancer survivors33. Metabolic 
V\QGURPHDOWHUQDWLYHO\NQRZQDVWKH³FDUGLRYDVFXODUULVNIDFWRUFOXVWHU´GXHWRLWVDVVRFLDWion 
with cardiovascular disease,  is particularly prevalent in patients who are exposed to total body, 
chest or abdominal radiation34. 
 
1.2.iv Respiratory Disease 
Respiratory disease has been less well studied than cardiovascular or endocrine disease, but 
nonetheless is known to disproportionately affect survivors of CYP cancer. 21% of survivors 
will have experienced at least one respiratory illness 35 years post diagnosis35. Patients who 
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have undergone chest radiation therapy have a cumulative incidence of 3.5% for pulmonary 
fibrosis 20 years after diagnosis36. Spinal and craniospinal irradiation is  similarly associated 
with increased risk of respiratory pathology37.  
 
1.2.v Neurological Disorders 
Neurological complications, other than strokes, are not especially prevalent amongst most CYP 
cancer survivors, but are increased in those who have been treated for central nervous system 
tumours; by 30 years post diagnosis, 41% will have experienced seizures, 35% will have motor 
impairment and 23% will have some degree of hearing loss38. 
 
1.2.vi Mental Health 
CYP cancer survivors are known to be at increased risk of mental health problems; those 
survivors with ongoing physical health problems being amongst those at greatest risk of mental 
ill health39. Those who are diagnosed in the TYA period appear much more likely to suffer 
mental health problems than those diagnosed at younger ages40.   
 
1.2.vii Sexual and Reproductive Health  
Problems with fertility41 42 and sexual health43 are strongly correlated with poor mental health. 
Equally, psychological factors are thought to be one reason why CYP cancer survivors develop 
problems with sexual function44. Sexual health problems are prevalent in survivors of CYP 
cancer; over 12% of males report erectile dysfunction, a rate around 4 times higher than non-
cancer controls45. In females, decreased arousal, pleasure and overall satisfaction with sexual 
function occur at an increased rate amongst cancer survivors than the general population46. 
Survivors of TYA cancers, who are faced with cancer treatment at the same time as going 
through puberty and discovering their sexuality, are at particular risk of sexual health 
problems47, despite having similar rates of engagement in sexual activity to their healthy peers48. 
Quality of life amongst survivors with reported sexual health problems is known to be reduced49. 
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2. CANCER AND FERTILITY.  
It is challenging to assess the full impact of cancer and treatment upon fertility. Classically 
amenorrhoea and pregnancy rates have been used as indicators amongst females and semen 
analysis or paternities have been used amongst male cancer survivors.  
 
2.1. Impact in males (Table 1) 
Although some forms of cancer itself, such as testicular, can have a significant direct impact on 
testicular health and function, for the purpose of this review the primary focus will be the impact 
of treatment rather than the disease process itself, accepting that it is not always possible to 
clearly differentiate these effects.  It must be remembered that the psychological, endocrine and 
other physical LEs described previously in this review may significantly impact on fertility. 
In males, the testis is the site of production of mature spermatozoa and testosterone. Given that 
cancer treatments can target both healthy and cancerous cell lines the spermatogonia and 
supporting cells are  at risk of damage50. However, testosterone producing, Leydig cells are more 
resistant to anticancer treatments than the germinal cell lines51 52 53 . Consequently most pre-
pubertal male patients, who receive cancer treatment will achieve normal pubertal development 
54
 
55
 
56
. Further research continues to try and establish the mechanisms by which different 
treatments lead to damage57 58.  
Green, et al, report that when compared with their siblings, survivors of childhood cancer were 
approximately half as likely to sire a pregnancy59. It remains unclear at  present whether there is 
a long term generational impact on the fertility of children born from male cancer survivors with 
a Danish study reporting no significant association60 but potential mechanisms of effect have 
been identified in animal work61. 
 
2.2. Impact in females (Table 1) 
The incidence of premature ovarian insufficiency has been reported at 6.5% in female childhood 
cancer survivors62. The risk of premature ovarian insufficiency appears to be connected to the  
underlying diagnosis, the type of chemotherapy administered (alkylating agents appear to have 
one of the highest impacts), the total cumulative dose of chemotherapy, the dose and site of 
radiation (with abdominal and pelvic irradiation providing highest risk) and whether single or 
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combination agents are used.63 64 65 66.  Should the menopause occur prior to the age of 40 it is 
GHILQHGDV³SUHPDWXUH´. This has been reported at 8% in female cancer survivors (RR of 13.21 
and 95% C.I 3.26-53.51; P<0.001) compared to sibling controls67 68. Even for women who do 
not fall into the category premature menopause evidence suggests that ovarian function ceases 
earlier within the group of childhood cancer survivors,  at a median age of 44 years69 compared 
to 51.4 years in the general population70. An expedited drop in the number of follicles in pre-
pubertal females treated for cancer may be responsible for a narrower window of reproductive 
function in childhood cancer survivors71.  
It remains unclear the exact mechanism by which chemotherapy damages the ovary, and 
potential sites of damage include; primordial follicles, developing follicles, somatic support cells 
and ovarian vasculature72 65. Evidence exists to support different models of damage and 
potentially different agents and treatment modalities may cause damage via differing 
mechanisms73 74 75 76. 
Whilst ovarian function is vital for conception, it must not be regarded in isolation. To achieve a 
successful live, term birth a holistic approach must be considered.  Uterine function along with 
overall physical, psychological and social health are important.  A woman must be systemically 
healthy enough to cope successfully with the physiological changes of both the ante-natal and 
post-natal periods. In both sexes there are multiple potential sites for disruption and damage to 
occur in the process of reproduction and different treatments and modalities may impact fertility 
at different sites and in different ways.  
Local effects on cancer treatment in both male and female survivors are summarised in Table 1. 
 
2.3. Pregnancy rates in childhood cancer survivors. 
Recently published population based data from Scotland (including patients up to the age of 40 
at the time of cancer diagnosis) suggests that female cancer survivors achieve fewer pregnancies 
than age matched general population controls. SIR 0.62 (95% CI: 0.60, 0.63)81. These results are 
reflected in previous smaller studies across the Scandinavia with a Swedish population based ± 
matched cohort study of patients aged <21 years at the time of their cancer diagnosis, reporting 
the probability of having a first live birth being significantly lower amongst survivors. In this 
study males were reported as having a lower hazard ratio [HR], than women (HR 0.65 v 0.79)82.  
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3. FERTILITY PRESERVATION 
3.1. Males 
In the post-pubertal male, sperm cryopreservation remains the gold standard option for fertility 
preservation83. In adolescent males, it is possible to cryopreserve semen in >80% of cases84. In 
pre-pubertal boys the absence of mature sperm within the gonads means that this is not an 
option. Research is ongoing into the area of testicular tissue and spermatogonial stem cell  
cryopreservation and the development of techniques that will allow for the production and 
maturation of gametes after thawing of immature tissue 85 86. Current strategies for restoring 
fertility after testicular or spermatogonial stem cell cryopreservation include; auto-
transplantation, via intra-testicular spermatogonial stem cell injection or testicular tissue thaw 
and surgical graft84. Promising evidence exists in these areas, particularly in murine models87 88 
89
 
90
. 
 
3.2. Females 
As with their male counterparts, post-pubertal females are potentially able to undergo mature 
gamete storage in the form of oocyte storage, or embryo (if appropriate) storage 83 91 92. Both 
mature oocyte storage and embryo storage require an ovarian stimulation cycle to yield an 
increase in oocyte production in a single cycle. In some cases, this would cause a delay to a 
patient¶s cancer treatment that would put their health, and survival at risk and therefore may not 
be appropriate. In regard to pre-pubertal patients, unlike in the male, a girl is born with her full 
complement of primordial ovarian follicles, at an arrested stage of development, within her 
ovarian cortex (her ovarian reserve). This has led to the development of techniques to harvest 
and cryopreserve ovarian cortex with a view to autologous transplantation in adult life. There 
have been more than 100 babies born internationally from this technique 93 94 95 96  and whilst the 
vast majority have been from ovarian tissue cryopreserved after the onset of puberty there have 
been published reports of successful pregnancies and live births from ovarian tissue 
cryopreserved before the onset of puberty97. Ovarian tissue cryopreservation may also be an 
option for post-pubertal female patients for whom a stimulation cycle is inappropriate.  
The ongoing research and successful outcomes in these areas are driving forward discussions 
and early fertility-preservation interventions with patients and their families at the point when 
they receive a diagnosis of cancer and their initial treatment plan is formulated. 
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3.3 Decision making in children in regard to fertility preservation. 
As healthcare has shifted over recent decades from a paternalistic approach to a shared decision-
making approach, tools are being developed to aid patients and their families when deciding 
upon options. In young adult survivors, studies have shown that fertility ranks highly amongst 
patients concerns98, and adolescents have a strong desire to participate in decisions related to 
their cancer and treatment99.  This must be taken into account by clinicians when discussing 
future reproductive health with children and young adults at the time of diagnosis of cancer and 
at later stages in their cancer journey including through adult survivorship.  Clinical teams need 
to be considerate of the competence and ability of the child or young adult to understand their 
disease, treatment, potential side-effects and fertility preservation options.  At the time of 
diagnosis with a life-threatening illness, patients and their families may find large volumes of 
information too much to deal with and it can be hard to focus on future considerations when 
faced with uncertainty regarding survival. Access to age-appropriate information may be 
beneficial and should be considered an essential part of clinical care provision100.  
Counselling and guidance of patients and their families is complicated by the difficulties in pin-
pointing an individual patient¶VULVNof infertility after treatment. The lack of specificity in  
clinical guidelines illustrate this92 101 102. Further research is required in this area. 
 
4. CANCER AND PREGNANCY 
Many survivors of childhood cancer are able to conceive naturally, whilst some may require 
assisted reproductive technologies. The maternal health of these patients should ideally be 
assessed and optimised prior to conception, with ongoing surveillance throughout the ante-natal 
and post-natal periods. 
 
4.1 Late effects of cancer and cancer treatment on maternal health 
As discussed previously cardiovascular, respiratory and metabolic factors are amongst the 
potential LEs facing survivors of childhood and young adult cancers. Pregnancy is known to 
increase the burden on the cardiorespiratory and endocrine systems and can lead to 
decompensation in women with pre-existing conditions 103 104 105. 
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Given the heterogeneity of cancer types and treatment regimes across the population of 
childhood cancer survivors it is important that patients are assessed on a one by one basis with 
regard to their diagnosis, treatment and potential LES (Table 2). Ideally preconception 
assessment and optimisation of known co-morbidities should occur. Antenatal care should be 
coordinated by an obstetrician and physician with expertise in their co-morbidities, if required106.  
When assessing a survivor of cancer preconceptionally or antenatally, one should be mindful 
that not all adverse effects will occur at the time of treatment and some may be delayed. For 
example, anthracycline related cardiotoxicity. Here the effects can occur many years later, and 
patients may be asymptomatic despite the damage107 108. For childhood cancer survivors treated 
with anthracyclines or radiation to the cardiac field regular assessment by echocardiography is 
recommended, particularly in the first and third trimester of pregnancy101. 
 
4.2. Late effects of cancer and cancer treatment on fetal health. 
Maternal health itself can have a direct impact on fetal outcomes as well as treatments the 
mother receives during pregnancy to manage her LEs of prior cancer treatment (Table 3). 
 
5. CONCLUSION 
As CYP cancer survival continues to improve and the prevalence of cancer survivors increases, 
health services are providing care for a growing number of adults at risk of LEs of a malignancy 
treated in the CYP age range. Whilst the majority are free of their cancer and are not thought to 
be sub-fertile, they are not always free of LEs of their treatment. Reproductive health is 
commonly cited as an important consideration to survivors of cancer and it is essential that 
clinical teams consider any potential reproductive health sequelae both prior to commencing and 
following anti-cancer treatment. Recent advances in fertility preservation techniques provide a 
new array of interventions to potentially minimise adverse reproductive health consequences of 
cancers and their treatments in the CYP community. )URPWKHRXWVHWRIDSDWLHQW¶VFDQFHU
journey, close liaison between oncology and reproductive health multi-disciplinary teams is 
advocated to ensure optimal provision of advice and care.  
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Table 1. Localised effects of cancer treatment in survivors 
 
POTENTIAL SIDE EFFECT: POTENTIAL IMPACT ON FERTILITY   
MALE 
Testicular: 
Impaired spermatogenesis  Reduced semen quality or azoospermia 
resulting in male factor infertility59, 77. 
Disruption of hypothalamic ± pituitary- 
gonadal axis 
Central infertility resulting in impaired 
spermatogenesis59. 
  
FEMALE 
Ovarian: 
Primordial Follicle Loss or Damage Premature ovarian insufficiency78, 79, 80.  
Uterine: 
Radiotherapy damage  Increased rates of early and late pregnancy 
loss80.  
Vaginal: 
Dryness/ strictures Dyspareunia 
Endocrine: 
Disruption of hypothalamic ± pituitary- 
gonadal axis 
Central infertility resulting in impaired 
folliculogenesis78. 
 
Based on Green et al. 201059, Green et al. 201477 ,  Green et al. 2009 78, Green et al. 200979,  Bath et al. 199980.
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Table 2. Late effects of cancer treatment and potential obstetric complications  
POTENTIAL LATE EFFECT: POTENTIAL OBSTETRIC CONSIDERATION:   
Cardiovascular: 
Increased rates of congestive heart failure OR 
cardiomyopathy 
Pregnancy itself will increase strain on the cardiovascular system with changes to support the placental vasculature supply. The 
immediate post-partum period sees rapid changes in the circulating volume. These changes can lead to decompensation in a 
patient with cardiovascular mortality106 119.  
Increased risk of myocardial infarction  
Pericardial disease 
Valvar heart disease 
Increased coronary artery disease 
Endocrine and Metabolic: 
Diabetes Diabetic control, even in previously well- controlled patients can become challenging in the antenatal period and there can be 
reduced awareness of hypoglycaemia110 111. 
Thyroid dysfunction Patients often require review and adjustment of their thyroid medication throughout pregnancy to remain euthyroid110 112. 
Venous Thromboembolism: 
Recurrence in pregnancy Given the prothrombotic state of pregnancy, patients predisposed to venous thrombo-embolism (VTE) are at risk of a recurrence. 
VTE remains one of the leading cause of maternal deaths worldwide113. 
Anticoagulation treatment Due to fetal side effects from warfarin, pregnant patients are often converted to a low molecular weight heparin throughout 
pregnancy with a postnatal review and recommencement of prior therapy. Antepartum and postpartum haemorrhages are more 
common in anticoagulated patients. Anaesthetic and operative complications can occur and spinal or epidural anaesthesia are 
often contraindicated113 115. 
Recurrence or Secondary Malignancy in Pregnancy: 
Treatment in pregnancy Increased pregnancy loss if treated in embryonal stage114. 
Ovarian tissue cryopreservation and transplant, and 
reintroduction of primary cancer risk 
Patients with ovarian tissue cryopreserved prior to treatment who then receive this tissue back to restore fertility are at risk of the 
reintroduction of their primary cancer from the transplanted tissue116. 
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Based on RCOG 2011106, Wallace and Swallow 2016109, Nelson-Piercy 2015 110, Meacham et al. 2009111, Jeffery et al. 2015 112, RCOG. 2018113, Basu et al. 2016114, Esposito et al. 2016115, 
Rosendahl et al. 2013116.
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Table 3. Potential fetal complications in pregnancies of female childhood cancer survivors  
POTENTIAL FETAL COMPLICATIONS: COMMENT:  
  
Miscarriage Increased rates have been reported in cancer survivors 117 118. 
Intrauterine Growth Restriction Increased rates have been reported in cancer survivors118. 
Prematurity Increased rates have been reported in cancer survivors118. 
Intrauterine death Not significantly increased unless high dose radiotherapy to pelvis118.  
Heritable cancer conditions This will depend on the index malignancy. In appropriate cases genetic 
counselling will be required.   
Congenital abnormalities No direct increase is reported118, although there are increased rates of congenital 
abnormalities amongst women with pre-existing diabetes120 121.  
Teratogenicity Anticoagulants such as warfarin are known to cause teratogenicity and fetal 
warfarin syndrome114.  
Treatment for recurrence or secondary cancers may also lead to teratogenic 
effects. 
Potential risk of congenital malformations or long-term health effects in 
offspring conceived with assisted reproductive technologies (ART). 
Several studies report increased rates of fetal growth restriction, low birth 
weight, prematurity, increased cardiovascular malformations, leukaemia and 
Hodgkin lymphoma in ART offspring. With some studies indicating there can be 
metabolic effects in the long-term health of these children with increased 
incidences of elevated blood pressure, total body fat and fasting glucose being 
reported122 123 124 125 126 127 128. 
Based on Green et al. 2002117, Critchley et al. 2005118, Critchley et al. 1992119, NICE. 2008120, Metzger et al. 2002121, Basu et al. 2016114, Davies et al.122, Pinborg et al. 2012123, Huntriss et al. 
2018124, Hart et al. 2018125, Giorgione et al. 2018126, Källén et al. 2010 127, Reigstad et al. 2016128. 
